Bpifrance

Mabqi, headquartered in Grabels, France, is a biopharmaceutical company specializing in immunotherapy. It operates an antibody discovery platform, enabling the identification and development of innovative, proprietary therapeutic molecules.

MB Therapeutics is a pharmaceutical company specializing in personalized medicine. It offers a patient-centric system for developing and producing customized medications, including evaluation services. The company excels in tailoring medication dosage, forms, and combining multiple active ingredients into a single unit, enabling healthcare professionals to enhance treatment precision and improve patient adherence.

NEBULA maps 3D macromolecule using dataset-free genAI and physics, enhancing drug target discovery, which forms the basis of all new drugs.

BiPER Therapeutics is a biotechnology company focused on developing and commercializing innovative therapeutic solutions. The company specializes in creating drugs that target critical proteins involved in the metabolism of cancer cells, aiming to overcome treatment resistance and enhance cancer cell survival. Their primary focus is on providing effective treatments for gastrointestinal cancers.

Vetbiolix is a veterinary biotechnology company dedicated to developing innovative therapeutic solutions for dogs and cats. The company focuses on the clinical development of first-in-class drug candidates aimed at treating and preventing diseases affecting pets, including periodontitis, osteoarthritis, and gut motility disorders. By prioritizing the creation of effective treatments for common health issues, Vetbiolix aims to enhance the quality of life for pets and their owners.

Theremia is a health technology company that leverages artificial intelligence to transform drug development, with a focus on neurological disorders. It employs advanced machine learning to optimize drug compounds for specific demographic groups, enhancing treatment effectiveness and reducing adverse effects.

Vaxinano is a biotechnology company founded in 2016, focused on the preclinical and pharmaceutical development of vaccines and drug delivery systems for both humans and animals. Building on 25 years of research and clinical trials led by Pr Didier Betbeder, Vaxinano specializes in creating prophylactic and therapeutic vaccines for infectious diseases. The company employs safe-by-design nanoparticles that adhere to green chemistry principles, facilitating the development of drugs targeting active biomolecules, proteins, and antigens. This innovative approach enables medical researchers to create new vaccines aimed at addressing untreated viral, bacterial, and parasitic diseases.

Vetbiolix is a veterinary biotechnology company dedicated to developing innovative therapeutic solutions for dogs and cats. The company focuses on the clinical development of first-in-class drug candidates aimed at treating and preventing diseases affecting pets, including periodontitis, osteoarthritis, and gut motility disorders. By prioritizing the creation of effective treatments for common health issues, Vetbiolix aims to enhance the quality of life for pets and their owners.

Biodol Therapeutics SAS is a biotechnology company based in Clapiers, France, established in 2015. The company focuses on developing innovative compounds for the treatment of chronic pain, specifically targeting the Receptor Tyrosine Kinase (RTK) FLT3, which plays a critical role in triggering and sustaining chronic neuropathic pain. Biodol Therapeutics' research indicates that inhibiting FLT3 can enhance the effectiveness of opioids, potentially reducing their risk of addiction and contributing to solutions for the opioid crisis. By creating extracellular inhibitors of the FLT3 receptor, the company aims to alleviate pain hypersensitivity, allodynia, and spontaneous pain while preserving normal nervous system function. Through academic partnerships, Biodol Therapeutics continues to advance its understanding of pain mechanisms and develop its proprietary therapeutic approaches.

SeaBeLife Biotech SAS is a biotechnology company based in Roscoff, France, established in 2019. The company focuses on developing innovative drug candidates aimed at treating acute pathologies, particularly acute liver and renal failure. SeaBeLife's products are derived from a family of patented molecules designed to block regulated necrosis, a type of regulated cell death. By targeting two synergistic pathways involved in various acute and chronic diseases, SeaBeLife aims to establish a new standard of care for patients with significant unmet medical needs. Through its research and development efforts, the company seeks to enhance patient outcomes and reduce complications associated with serious health conditions.

ABIONYX Pharma SA is a French biopharmaceutical company established in 2005, currently based in Labege. It specializes in the discovery and development of therapies targeting high-density lipoprotein (HDL) for treating cardiovascular and metabolic diseases. The company's primary focus is on developing HDL mimetics to rapidly regress atherosclerotic plaque in high-risk patients. Its lead product candidate, CER-001, is a Phase II clinical trial asset designed to mimic the properties of pre-beta HDL for treating post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients. Additionally, ABIONYX Pharma has another drug candidate, CER-209, in Phase I trials for metabolic diseases and liver-related conditions such as atherosclerosis and non-alcoholic steato-hepatitis.

AQEMIA is a pharmaceutical technology company specializing in drug discovery. It employs a proprietary platform that integrates quantum-inspired physics with machine learning algorithms to accelerate and enhance the identification of new drug candidates tailored to specific therapeutic targets. This innovative approach enables AQEMIA to generate a robust pipeline of novel drug leads, aiming to improve efficiency and accuracy in predicting the affinity between drug candidates and their intended targets.

Eligo Bioscience S.A.S is a biotechnology company founded in 2014 and based in Paris, France, specializing in the development of Eligobiotics, a novel class of antimicrobials. These therapeutics are designed to target specific bacteria based on their genomic information, utilizing a combination of CRISPR/Cas technology and engineered phage capsids. This advanced approach allows Eligo to create precision antibiotics aimed at eradicating resistant pathogens and virulent bacteria within the human microbiome. The applications of Eligobiotics extend beyond pharmaceuticals; they also encompass areas such as cosmetics and biodefense, addressing a variety of bacteria-associated diseases and offering next-generation solutions to combat superbugs.

Quobly is a developer of quantum computing semiconductors focused on creating and marketing a universal large-scale quantum computer. By utilizing established semiconductor industry procedures, the company aims to commercialize quantum computers based on silicon. Quobly's technology is designed to address complex problems, such as optimizing energy distribution and computing chemical properties, which can accelerate the development of new drugs. The company provides clients with customized quantum computing solutions that leverage proven semiconductor processes to meet their specific needs.

Kairos Discovery is a biotechnology company focused on developing innovative targeted cancer therapies. The firm aims to create medicinal chemistry solutions that have the potential to significantly improve the lives of cancer patients and their families. By employing a first-in-class approach, Kairos Discovery targets essential cellular mechanisms that contribute to the survival and aggressiveness of both solid tumors and hematological cancers. This commitment to breakthrough oncology technology positions the company as a key player in the advancement of cancer treatment.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, specializing in the development of innovative therapies for advanced liver diseases and cancers associated with Claudin-1 (CLDN1) expression. Founded in 2019, Alentis focuses on addressing conditions such as liver fibrosis, cirrhosis, and liver cancer through the use of anti-CLDN1 antibody-drug conjugates and other targeted treatments. The company's unique approach combines clinically relevant read-outs with advanced techniques like single-cell RNA sequencing of patient liver tissues, aiming to reverse disease progression and improve patient outcomes. Alentis Therapeutics is recognized for its pioneering role in exploring anti-CLDN1 therapeutics, contributing to advancements in the treatment of fibrotic diseases and CLDN1-positive tumors.

Odimma is a biotech company specializing in precision medicine aimed at developing personalized cancer immunotherapy solutions. The company has created an innovative immunotherapy drug that harnesses a unique platform, integrating three specific immune components designed to work together with the patient's immune system. When administered, this approach aims to induce and enhance immune responses, providing patients with the potential to eliminate tumors while minimizing adverse side effects. Through its focus on personalized treatment strategies, Odimma seeks to improve outcomes for cancer patients by tailoring therapies to individual needs.

Hemerion is a biotechnology company dedicated to developing innovative treatments for cancer, with a particular emphasis on glioblastoma, the most common and aggressive primary brain tumor. The company's platform integrates advanced therapeutic services that combine surgical techniques with photonics, utilizing a photosensitizing drug designed to selectively target and destroy cancer cells. This approach allows for effective treatment in areas that are difficult to reach with traditional surgical methods while preserving healthy tissue. Hemerion's mission is to enhance the capabilities of healthcare professionals in addressing the challenges posed by brain cancer and to improve patient outcomes in their battle against glioblastoma.

Kayentis is a global leader in electronic clinical outcome assessment (eCOA) and Decentralized Clinical Trial solutions, focused on enhancing the efficiency and quality of data collection in clinical trials for the pharmaceutical, biotech, and contract research organization sectors. Founded in 2005, the company has specialized in eCOA solutions across various phases of clinical development, addressing over 200 indications in more than 20 therapeutic areas. Kayentis has adapted to the evolving clinical research landscape by offering a comprehensive suite of services aimed at supporting science-driven and patient-centric approaches. With operational capabilities spanning the USA, Europe, and Asia, Kayentis provides a range of adaptable tools to streamline electronic data capture, simplifying the clinical trial process for both patients and research sites.

AlgoTherapeutix is a biotechnology company focused on developing innovative topical treatments for patients suffering from difficult-to-treat conditions, particularly complex pain syndromes. The company targets damaged nerve fibers in the skin to provide localized pain relief while minimizing the systemic side effects often associated with oral medications. AlgoTherapeutix is actively advancing its lead product, ATX01, which has received FDA approval to enter Phase 2 clinical trials for chemotherapy-induced peripheral neuropathy, a painful condition that lacks proven therapeutic options. Additionally, the company is exploring the potential of its treatments for erythromelalgia, a rare and debilitating disorder characterized by severe pain and inflammation. By tailoring therapies to the specific needs of patients, AlgoTherapeutix aims to improve treatment outcomes for individuals facing these challenging health issues.

NFL Biosciences is a biotechnology company focused on developing solutions for tobacco addiction. The company specializes in research and development of medicines that utilize both botanical and pharmaceutical agents to aid individuals attempting to quit smoking. Its primary product, NFL-101, is a clinically developed botanical drug designed specifically to target smoking addiction. This innovative treatment contains minimal amounts of nicotine and is formulated from well-characterized natural tobacco leaf proteins, offering a unique approach to support smokers in overcoming their addiction.

BiPER Therapeutics is a biotechnology company focused on developing and commercializing innovative therapeutic solutions. The company specializes in creating drugs that target critical proteins involved in the metabolism of cancer cells, aiming to overcome treatment resistance and enhance cancer cell survival. Their primary focus is on providing effective treatments for gastrointestinal cancers.

Pasqal SAS, founded in 2019 and headquartered in Paris, France, specializes in the manufacture of quantum information processors utilizing atomic arrays. The company focuses on developing full-stack quantum computing technology that simulates complex phenomena to facilitate scientific discovery. Its innovative approach employs qubits made of neutral atoms organized in large two-dimensional and three-dimensional arrays, which enables analog computing. This technology addresses a variety of challenges, including optimization, drug discovery, and machine learning, empowering organizations to tackle complex problems across these fields.

NFL Biosciences is a biotechnology company focused on developing solutions for tobacco addiction. The company specializes in research and development of medicines that utilize both botanical and pharmaceutical agents to aid individuals attempting to quit smoking. Its primary product, NFL-101, is a clinically developed botanical drug designed specifically to target smoking addiction. This innovative treatment contains minimal amounts of nicotine and is formulated from well-characterized natural tobacco leaf proteins, offering a unique approach to support smokers in overcoming their addiction.

Jalon Therapeutics is a biotechnology company focused on developing innovative therapies that inhibit critical yet untargeted tumor signaling pathways. By exploring non-oncogene addiction, the company aims to identify new therapeutic targets and create effective anticancer treatment strategies. Through its research and development efforts, Jalon Therapeutics is dedicated to transforming the lives of cancer patients by providing novel medications that address unmet medical needs in oncology.

Livmed's is a software platform based in Nice, France, that specializes in home medicine delivery services. Founded in 2020, the company enables individuals to receive both prescription and non-prescription medications directly at their homes. The platform operates around the clock, ensuring timely access to essential healthcare products. Livmed's facilitates medicine delivery from local drugstores, allowing customers to obtain their medications conveniently, whether they have a prescription or not. Through its innovative approach, Livmed's enhances accessibility to healthcare while streamlining the medication procurement process for users.

Lys Therapeutics is a biotechnology company focused on developing therapies for patients with neurovascular and neurodegenerative disorders. The company is notable for its lead drug, Glunozumab, a monoclonal antibody that employs a novel mechanism of action. This drug hyperactivates both vascular and neuronal NMDA receptors, leading to off-target toxicity that can disrupt the blood-brain and blood-spinal cord barriers, resulting in neuronal excitotoxicity associated with conditions such as stroke and multiple sclerosis. Lys Therapeutics aims to address neuroinflammation and its effects on neurodegeneration through innovative biotherapies.

Valneva is a biopharmaceutical company specializing in the development, manufacturing, and distribution of prophylactic vaccines for infectious diseases. Its portfolio comprises two commercially available vaccines (IXIARO/JESPECT for Japanese encephalitis and DUKORAL for traveler's diarrhea), along with vaccine candidates targeting Lyme disease, chikungunya virus, and COVID-19. Valneva operates through segments including Commercialized Vaccines, Covid-19 Vaccine, Vaccine Candidates, and Technologies & Services. The company aims to address significant unmet medical needs in infectious diseases by leveraging its expertise and capabilities to advance vaccine candidates through clinical trials and ultimately commercialize them.

Guerbet is a healthcare company focused on medical imaging, with a history spanning 90 years. As a pioneer in contrast media, it is the only pharmaceutical group dedicated exclusively to this field. Guerbet operates in nearly 80 countries through a network of subsidiaries and distributors, providing a wide array of products for various imaging modalities, including CT scans, magnetic resonance imaging (MRI), ultrasound, and nuclear medicine. The company’s portfolio includes well-known brands such as Xenetix, Optiray, Dotarem, and Telebrix, among others. Additionally, Guerbet offers injectors and related medical devices aimed at enhancing patient diagnosis, prognosis, and overall quality of life.

Apmonia Therapeutics is a biotechnology company focused on developing next-generation peptide-based therapies aimed at targeting the tumor microenvironment to enhance cancer treatment. The company is dedicated to creating innovative drugs for various types of cancer, including glioblastoma, ovarian, colorectal, and pancreatic cancers. By offering new therapeutic perspectives, Apmonia aims to improve the lives of cancer patients and support researchers in developing personalized immunotherapy approaches. Their proprietary therapeutic peptides are designed to provide effective strategies for treating solid tumors, thereby contributing to advanced cancer care.

Carroucell is a supplier of microcarriers specifically designed for cell culture in bioreactors. The company has developed a unique platform featuring flat-shaped microcarriers made from a glass xenofree composition. This innovative design aims to enhance the efficiency of biomanufacturing by addressing common challenges associated with cell culture performance. Through its specialized products, Carroucell supports advancements in the field of cell culture, contributing to the overall improvement of biotechnological processes.

DeepLife is a biotech company founded in 2019 and based in Paris, France. The company specializes in developing digital twins of cells to enhance drug discovery processes. By utilizing deep learning techniques on multi-omics data, DeepLife models cellular behavior and simulates responses to various genetic screenings, such as siRNA and CRISPR-Cas9. This innovative approach aims to identify new targets, biomarkers, and potential drug candidates, while also addressing drug resistance and sensitivity. DeepLife operates in a collaborative manner, working alongside academic institutions to ensure a smooth transition from laboratory discoveries to patient applications. The company focuses on leveraging state-of-the-art technologies in systems biology and machine learning to identify molecular triggers that restore cells to their healthy states, thereby accelerating the target identification processes for biotech and pharmaceutical firms.

Qairn is a company that specializes in digitizing regulatory processes through its software-as-a-service (SaaS) platform. This platform is designed to streamline and secure mandatory procedures for various healthcare sectors, including laboratories, medical device manufacturers, and biotechnology firms. Qairn offers services such as the review and validation of promotional materials, submission to the ANSM, and the validation of regulated content. By simplifying these processes, Qairn helps healthcare manufacturers manage their regulatory requirements efficiently, thereby reducing risks associated with compliance and enhancing workflow management.

DBV Technologies S.A. is a clinical-stage biopharmaceutical company headquartered in Montrouge, France, focused on developing innovative treatments for food allergies through epicutaneous immunotherapy. The company's lead candidate, Viaskin Peanut, has completed Phase III clinical trials for the treatment of peanut allergies in children, adolescents, and adults. Additionally, DBV Technologies is advancing Viaskin Milk, which is in Phase I/II trials for cow’s milk protein allergy and related conditions, and Viaskin Egg, currently in pre-clinical development for hen’s egg allergy. The company is also exploring a booster vaccine for Bordetella pertussis and has ongoing research programs targeting respiratory syncytial virus, Crohn’s disease, celiac disease, and type I diabetes. Notably, DBV Technologies collaborates with Nestlé Health Science to develop MAG1C, an atopy patch test aimed at diagnosing non-IgE mediated cow’s milk protein allergy in infants and toddlers. Founded by pediatricians and entrepreneurs in 2002, DBV Technologies aims to revolutionize the field of immunotherapy by safely activating the immune system through its proprietary Viaskin technology.

Hemerion is a biotechnology company dedicated to developing innovative treatments for cancer, with a particular emphasis on glioblastoma, the most common and aggressive primary brain tumor. The company's platform integrates advanced therapeutic services that combine surgical techniques with photonics, utilizing a photosensitizing drug designed to selectively target and destroy cancer cells. This approach allows for effective treatment in areas that are difficult to reach with traditional surgical methods while preserving healthy tissue. Hemerion's mission is to enhance the capabilities of healthcare professionals in addressing the challenges posed by brain cancer and to improve patient outcomes in their battle against glioblastoma.

Ribonexus is a biotechnology company dedicated to developing innovative therapies aimed at treating cancer. The firm focuses on creating a pipeline of small molecules that specifically target the eukaryotic translation initiation factor-4A to address resistance in patients who have become unresponsive to existing targeted therapies. With a primary emphasis on melanoma, Ribonexus aims to enhance the effectiveness of current treatments by restoring sensitivity to them in patients whose cancers have developed resistance. Through its research and development efforts, Ribonexus seeks to contribute meaningful advancements in oncology and improve treatment outcomes for patients facing challenging cancer types.

Ribonexus is a biotechnology company dedicated to developing innovative therapies aimed at treating cancer. The firm focuses on creating a pipeline of small molecules that specifically target the eukaryotic translation initiation factor-4A to address resistance in patients who have become unresponsive to existing targeted therapies. With a primary emphasis on melanoma, Ribonexus aims to enhance the effectiveness of current treatments by restoring sensitivity to them in patients whose cancers have developed resistance. Through its research and development efforts, Ribonexus seeks to contribute meaningful advancements in oncology and improve treatment outcomes for patients facing challenging cancer types.

Priothera Ltd is a clinical-stage biotechnology company based in Dublin, Ireland, with an additional location in Saint Louis, France. Founded in 2020, Priothera specializes in the development of orally administered sphingosine 1 phosphate (S1P) receptor modulators aimed at treating haematological malignancies. The company's leading candidate, mocravimod, is designed to reduce the egress of T cell subsets from lymphatic tissue, thereby enhancing the curative potential of allogeneic hematopoietic stem cell transplantation. By providing dual inhibition of graft versus host disease while promoting graft versus leukemia effects, Priothera aims to significantly improve outcomes for patients undergoing such transplants.

Brenus Pharma is a biotechnology company focused on developing innovative allogeneic cell-based immunotherapies aimed at treating solid tumors. The company specializes in creating anti-cancer cell vaccines that leverage the patient’s immune system to prevent cancer resistance during treatment. With a strong emphasis on derisking strategies, Brenus Pharma generates multiple candidates efficiently, allowing for cost-effective scaling and a strategic entry into the market alongside established standards of care. The company boasts a robust intellectual property portfolio and a highly skilled team, including renowned oncologists, who work to educate the immune system to recognize tumor-associated and tumor-specific antigens. This approach enhances the potential for effective responses in cancer treatment.

SeaBeLife Biotech SAS is a biotechnology company based in Roscoff, France, established in 2019. The company focuses on developing innovative drug candidates aimed at treating acute pathologies, particularly acute liver and renal failure. SeaBeLife's products are derived from a family of patented molecules designed to block regulated necrosis, a type of regulated cell death. By targeting two synergistic pathways involved in various acute and chronic diseases, SeaBeLife aims to establish a new standard of care for patients with significant unmet medical needs. Through its research and development efforts, the company seeks to enhance patient outcomes and reduce complications associated with serious health conditions.

AlgoTherapeutix is a biotechnology company focused on developing innovative topical treatments for patients suffering from difficult-to-treat conditions, particularly complex pain syndromes. The company targets damaged nerve fibers in the skin to provide localized pain relief while minimizing the systemic side effects often associated with oral medications. AlgoTherapeutix is actively advancing its lead product, ATX01, which has received FDA approval to enter Phase 2 clinical trials for chemotherapy-induced peripheral neuropathy, a painful condition that lacks proven therapeutic options. Additionally, the company is exploring the potential of its treatments for erythromelalgia, a rare and debilitating disorder characterized by severe pain and inflammation. By tailoring therapies to the specific needs of patients, AlgoTherapeutix aims to improve treatment outcomes for individuals facing these challenging health issues.

Diaccurate is a biotechnology company based in Paris, France, founded in 2012. The company focuses on researching and developing innovative treatments for various medical conditions, including HIV infection, endocrine-resistant metastatic breast tumors, glioblastoma, and refractory acute myeloid leukemia. Diaccurate is dedicated to exploring new frontiers in oncology to create novel therapeutic approaches aimed at combating difficult-to-treat cancers and improving patient outcomes.

Emergence Therapeutics AG is a biopharmaceutical company based in Duisburg, Germany, focused on developing innovative antibody-drug conjugates (ADCs) to address high-need cancers. Established in 2019, the company leverages advanced technologies in antibody design, linker systems, and therapeutic payloads to create targeted treatments. Its lead program specifically targets Nectin-4, a clinically validated marker for various cancers, utilizing a highly specific antibody in combination with optimized linker technology and amanitin as the payload. This approach aims to provide effective therapeutic options for challenging cancer types. Emergence Therapeutics is also exploring opportunities to develop additional first- or best-in-class ADCs to meet unmet medical needs in oncology.

MedinCell S.A. is a pharmaceutical company focused on developing innovative therapeutic solutions through its proprietary BEPO technology, which facilitates long-acting injectable products utilizing biodegradable polymers and a biocompatible solvent. Based in Jacou, France, the company is engaged in ongoing research and development to optimize the efficiency and accessibility of medical treatments across various therapeutic areas. MedinCell's product pipeline includes several candidates, such as mdc-IRM, a subcutaneous injection for schizophrenia currently in Phase III trials, and mdc-CWM, an intra-articular injection aimed at treating pain and inflammation. Additionally, the company is exploring formulations like mdc-WWM for contraception and mdc-ANG for central nervous system disorders, alongside other candidates targeting pain management and organ transplant applications. Through its advancements in controlled, long-acting injectables, MedinCell aims to enhance treatment outcomes for patients.

Perha Pharmaceuticals is a biotechnology company dedicated to the research and development of innovative therapies, particularly focusing on kinase inhibitors. The company explores natural marine substances as a foundation for its drug discovery efforts, optimizing molecules derived from marine organisms. Perha Pharmaceuticals aims to address significant medical challenges, including the prevention of cisplatin-induced hearing loss and the treatment of cognitive disorders associated with Down syndrome and Alzheimer's disease. Through its targeted approach, the company seeks to provide effective solutions for patients suffering from hearing loss and related cognitive impairments.

Egle Therapeutics SAS is a biotechnology company founded in 2020 and based in Paris, France. The company specializes in developing immunotherapies aimed at targeting immune suppressor regulatory T-cells (Tregs) to address oncology and autoimmune diseases. Egle Therapeutics is focused on its proprietary pipeline, which includes a series of computationally designed IL-2 variants designed to modulate Tregs by either engaging or disengaging them from tumor environments. Through its innovative approach to Treg modulation, the company aims to enable healthcare professionals to develop new therapies that effectively target these immune suppressor cells, potentially transforming treatment options for cancer and other diseases.

Provepharm Life Solutions SA is a life sciences company based in Marseille, France, specializing in contract research and development services for small molecules and therapeutic peptides. Founded in 1998, the company focuses on the development, manufacturing, and marketing of pharmaceutical products and active ingredients. A key offering is pharmacopoeial grade methylene blue, a versatile compound utilized in various human health applications, including as an antidote for methemoglobinemia, a mild urinary antiseptic, and a topical antiseptic. The company also addresses animal health needs, providing solutions for toxicosis and aquaculture. Methylene blue serves additional roles as a laboratory dye, indicator, and diagnostic aid in surgical procedures. Provepharm Life Solutions aims to lead in the life sciences sector through its innovative approach, known as Molecule Vitalization, and offers a range of research and manufacturing services to advance health solutions.

Inotrem S.A. is a biotechnology company focused on developing innovative immunotherapies for acute and chronic inflammatory conditions. The company specializes in targeting the TREM-1 pathway to modulate unbalanced inflammatory responses. Inotrem's proprietary technology platform has led to the creation of nangibotide (LR12), a first-in-class TREM-1 inhibitor with potential applications in critical medical situations such as septic shock and myocardial infarction. Additionally, Inotrem is advancing research on new therapeutic modalities aimed at addressing chronic inflammatory diseases. By leveraging its expertise in immunomodulation, Inotrem aims to provide effective treatments for patients suffering from various inflammatory syndromes, enhancing critical care solutions in healthcare.

METabolic EXplorer, founded in 1999 and headquartered in Saint-Beauzire, France, is a biochemistry company specializing in the development of industrial fermentation processes as sustainable alternatives to petrochemical methods. The company produces functional ingredients from natural origins for use in cosmetics, nutrition-animal health products, and biomaterials synthesis. By leveraging bacterial biochemistry, METabolic EXplorer aims to create viable, long-term solutions based on renewable resources, focusing on economic performance and competitiveness. The company continually works to enhance the efficiency of microorganisms and diversify the supply of renewable raw materials to produce essential chemical compounds with wide-ranging industrial applications.

Alkion BioInnovations, established in March 2017, focuses on the development of innovative cannabinoid and pharmaceutical active pharmaceutical ingredients (APIs) through large-scale plant tissue production. The company employs proprietary semi-industrial technologies to produce natural plant active ingredients aimed at the pharmaceutical and agri-food markets. In addition to its work with cannabinoids, Alkion is also developing a novel plant-based high-intensity protein sweetener as a sugar replacement. The company has received numerous research and development grants and accolades, underscoring its commitment to advancing disruptive nutrition, non-cosmetic oils, and agrochemicals derived from plant sources.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, specializing in the development of innovative therapies for advanced liver diseases and cancers associated with Claudin-1 (CLDN1) expression. Founded in 2019, Alentis focuses on addressing conditions such as liver fibrosis, cirrhosis, and liver cancer through the use of anti-CLDN1 antibody-drug conjugates and other targeted treatments. The company's unique approach combines clinically relevant read-outs with advanced techniques like single-cell RNA sequencing of patient liver tissues, aiming to reverse disease progression and improve patient outcomes. Alentis Therapeutics is recognized for its pioneering role in exploring anti-CLDN1 therapeutics, contributing to advancements in the treatment of fibrotic diseases and CLDN1-positive tumors.

Pasqal SAS, founded in 2019 and headquartered in Paris, France, specializes in the manufacture of quantum information processors utilizing atomic arrays. The company focuses on developing full-stack quantum computing technology that simulates complex phenomena to facilitate scientific discovery. Its innovative approach employs qubits made of neutral atoms organized in large two-dimensional and three-dimensional arrays, which enables analog computing. This technology addresses a variety of challenges, including optimization, drug discovery, and machine learning, empowering organizations to tackle complex problems across these fields.

AQEMIA is a pharmaceutical technology company specializing in drug discovery. It employs a proprietary platform that integrates quantum-inspired physics with machine learning algorithms to accelerate and enhance the identification of new drug candidates tailored to specific therapeutic targets. This innovative approach enables AQEMIA to generate a robust pipeline of novel drug leads, aiming to improve efficiency and accuracy in predicting the affinity between drug candidates and their intended targets.

Biophytis SA is a clinical-stage biotechnology company headquartered in Paris, France, dedicated to developing therapeutics aimed at slowing the degenerative processes associated with aging and enhancing functional outcomes for patients with age-related diseases. The company is focused on activating key biological resilience pathways that may protect against the effects of various biological and environmental stresses linked to these diseases. Biophytis's lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule designed for treating neuromuscular conditions such as sarcopenia and Duchenne muscular dystrophy. Additionally, its second candidate, Macuneos (BIO201), targets retinal diseases, including age-related macular degeneration and Stargardt disease. The company has established a collaboration agreement with AFM-Telethon to further the development of Sarconeos. Since its founding in 2006, Biophytis has aimed to position itself as a leader in the emerging field of aging science by providing innovative therapies for patients with limited treatment options.

Biophytis SA is a clinical-stage biotechnology company headquartered in Paris, France, dedicated to developing therapeutics aimed at slowing the degenerative processes associated with aging and enhancing functional outcomes for patients with age-related diseases. The company is focused on activating key biological resilience pathways that may protect against the effects of various biological and environmental stresses linked to these diseases. Biophytis's lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule designed for treating neuromuscular conditions such as sarcopenia and Duchenne muscular dystrophy. Additionally, its second candidate, Macuneos (BIO201), targets retinal diseases, including age-related macular degeneration and Stargardt disease. The company has established a collaboration agreement with AFM-Telethon to further the development of Sarconeos. Since its founding in 2006, Biophytis has aimed to position itself as a leader in the emerging field of aging science by providing innovative therapies for patients with limited treatment options.

Step Pharma, incorporated in 2014 and based in Paris, France, focuses on developing innovative drugs for immunosuppressive therapies aimed at treating autoimmune diseases. As a spin-off of the Imagine Institute, the company emerged from research led by Pr. Alain Fischer on genetic immunodeficiencies. It operates as a joint venture with Sygnature Discovery, which provides integrated drug discovery resources, and Kurma Partners, a prominent investor in European healthcare and biotechnology. Step Pharma's proprietary small molecule therapeutics utilize a novel class of oral nucleotide synthesis inhibitors that target cytidine triphosphate synthase 1. This approach allows for the selective modulation of immune cell populations, such as T and B cells, enhancing treatment efficacy and therapeutic outcomes for patients with autoimmune conditions.

Seekyo is a private biotech company focused on advancing chemotherapy treatments that specifically target the microenvironment of solid tumors. By employing innovative smart drugs, Seekyo aims to deliver potent anticancer agents in a manner that minimizes harm to healthy tissues. Their approach includes a versatile enzyme-responsive self-immolative linker that facilitates the controlled release of the drug exclusively at the tumor site. This technology enables efficient recognition of malignant characteristics, allowing for targeted and effective treatment while significantly reducing adverse effects for cancer patients.

CVasThera is a biopharmaceutical company focused on developing innovative therapies for cardiovascular and bowel diseases, with a particular emphasis on treating conditions such as Crohn's disease. The company benefits from an exclusive global license for two patents, which are the result of four years of collaborative research involving the French National Institute of Health and Medical Research and the École des Mines d’Albi. By leveraging this research, CVasThera aims to create effective treatments for patients experiencing moderate to severe flare-ups, particularly those reliant on corticosteroids.

Iktos is a French scale-up company focused on applying artificial intelligence and robotic technologies to medicinal chemistry and drug design. The company has developed a proprietary generative AI solution that optimizes small molecules in silico, enhancing productivity in pharmaceutical research and development. Iktos offers its expertise through its SaaS platforms, Makya™ for generative drug design and Spaya™ for retrosynthesis, while also collaborating with pharmaceutical companies to accelerate drug discovery processes. Additionally, Iktos has created Iktos Robotics, an AI-driven automation platform that significantly speeds up the Design-Make-Test-Analyze cycle in drug discovery. The company is also advancing its own pipeline of drug candidates aimed at oncology and autoimmune diseases. In 2023, Iktos completed a significant financing round and, in 2024, expanded its capabilities through the acquisition of Synsight, integrating a biology platform focused on discovering new drugs that target Protein-Protein Interactions and RNA-Protein Interactions.

NovAliX is a research organization specializing in drug discovery and pharmaceutical development. It provides a range of integrated services designed to address the outsourcing needs of the pharmaceutical industry, from initial discovery through to manufacturing. Utilizing proprietary technologies such as surface plasmon resonance (SPR), X-ray protein crystallography, and advanced NMR techniques, NovAliX offers comprehensive support for small molecule drug discovery and biologics characterization. The company's collaborative approach enables clients to access a unique combination of screening, medicinal chemistry, and structural biology, facilitating the development of effective drugs. Additionally, NovAliX conducts thorough analyses of active pharmaceutical ingredients (APIs) and polymorphism studies, supporting pharmaceutical development and manufacturing teams in their efforts to bring new therapies to market.

Kayentis is a global leader in electronic clinical outcome assessment (eCOA) and Decentralized Clinical Trial solutions, focused on enhancing the efficiency and quality of data collection in clinical trials for the pharmaceutical, biotech, and contract research organization sectors. Founded in 2005, the company has specialized in eCOA solutions across various phases of clinical development, addressing over 200 indications in more than 20 therapeutic areas. Kayentis has adapted to the evolving clinical research landscape by offering a comprehensive suite of services aimed at supporting science-driven and patient-centric approaches. With operational capabilities spanning the USA, Europe, and Asia, Kayentis provides a range of adaptable tools to streamline electronic data capture, simplifying the clinical trial process for both patients and research sites.

OSE Immunotherapeutics SA is a clinical-stage biotechnology company based in Nantes, France, specializing in the development of innovative immunotherapies aimed at immune activation and regulation, particularly in the areas of immuno-oncology and autoimmune diseases. The company's product portfolio includes Tedopi, which is in Phase III clinical trials for lung cancer and Phase II for pancreatic cancer; BI 765063, currently in Phase I trials for solid tumors; and OSE-703, a humanized monoclonal antibody in preclinical development for various cancers. Additionally, OSE Immunotherapeutics is advancing FR104, which is in Phase I trials for rheumatoid arthritis, and OSE-127, a humanized monoclonal antibody in Phase I trials for inflammatory autoimmune diseases. The company collaborates with notable partners such as GERCOR, Memorial Sloan Kettering Cancer Center, Boehringer Ingelheim, Servier, and HalioDx. OSE Immunotherapeutics was previously known as OSE Pharma SA before its name change in May 2016.

AlgoTherapeutix is a biotechnology company focused on developing innovative topical treatments for patients suffering from difficult-to-treat conditions, particularly complex pain syndromes. The company targets damaged nerve fibers in the skin to provide localized pain relief while minimizing the systemic side effects often associated with oral medications. AlgoTherapeutix is actively advancing its lead product, ATX01, which has received FDA approval to enter Phase 2 clinical trials for chemotherapy-induced peripheral neuropathy, a painful condition that lacks proven therapeutic options. Additionally, the company is exploring the potential of its treatments for erythromelalgia, a rare and debilitating disorder characterized by severe pain and inflammation. By tailoring therapies to the specific needs of patients, AlgoTherapeutix aims to improve treatment outcomes for individuals facing these challenging health issues.

Advicenne is a late-stage biopharmaceutical company established in 2007 and headquartered in Nîmes, France. It focuses on developing and commercializing innovative treatments for unmet medical needs in nephrology, particularly for orphan renal diseases and niche neurology indications. The company's lead drug candidate, ADV7103, is currently undergoing late-stage clinical trials for two specific conditions: distal renal tubular acidosis (dRTA) and cystinuria. Advicenne aims to create pediatric-friendly therapeutics that enhance the quality of life for patients from early childhood through adulthood.

VectivBio AG is a clinical-stage biotechnology company based in Basel, Switzerland, founded in 2019 as a spinout from Therachon. The company specializes in the discovery, development, and commercialization of innovative treatments for severe rare diseases, particularly those with significant unmet medical needs. Its lead product candidate, Apraglutide, is a synthetic GLP-2 analog designed to enhance the intestine’s ability to absorb fluids and nutrients, thereby reducing the reliance on parenteral support in patients with short bowel syndrome. VectivBio is dedicated to developing best-in-disease therapies that aim to meaningfully improve the lives of patients and their families, providing more than just incremental advancements over existing standard-of-care options.

TISSIUM is a medical device company headquartered in Paris, France, focused on the development and commercialization of innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, provide strong adhesion to tissues, and enable rapid wound closure in the body's dynamic environments. TISSIUM leverages advanced research and intellectual property from renowned laboratories, including those of Robert Langer at MIT and Jeff Karp at Brigham and Women’s Hospital. Its technology platform includes a proprietary family of fully biosynthetic, biomorphic, and programmable polymers, which are tailored for tissue reconstruction across various clinical applications. Founded in 2013, TISSIUM is supported by leading healthcare investors and aims to address unmet clinical needs through its groundbreaking approach to wound management.

SideROS is a biotechnology company based in Paris, France, focused on developing innovative treatments for cancer. Founded in 2019, it specializes in research on iron-targeting chemical compounds aimed at attacking persister cancer cells, which are resistant to conventional therapies and often lead to metastasis and relapse. The company's primary candidate, ironomycin, disrupts iron homeostasis in these cells, inducing cell death through a process known as ferroptosis. By targeting the unique vulnerabilities of persister cancer cells, SideROS aims to provide new therapeutic options for patients facing challenging cancer cases.

Synapse Medicine is a company based in Bordeaux, France, that specializes in developing an online medical intelligence platform aimed at improving drug prescription management for healthcare professionals. Founded in 2017, the company has created a comprehensive knowledge base that utilizes algorithms to deliver reliable and up-to-date information about medications. This platform allows doctors and pharmacists to analyze treatment options in real time, ensuring the safety and efficacy of drug therapies. By working with leading hospitals and digital health companies across the United States, Europe, and Japan, Synapse Medicine is committed to transforming medication management and enhancing patient care through innovative technology solutions.

ABC Transfer is a biopharmaceutical company specializing in the development of Rapid Transfer Systems (RTS) solutions. It manufactures secure transfer systems specifically designed for sterile drug manufacturing and bioprocessing. The company's innovative systems utilize patented components such as alpha doors, beta containers, and single-use bags. These systems enhance sterility assurance, promote operator safety, and improve overall efficiency in pharmaceutical manufacturing processes.

SeaBeLife Biotech SAS is a biotechnology company based in Roscoff, France, established in 2019. The company focuses on developing innovative drug candidates aimed at treating acute pathologies, particularly acute liver and renal failure. SeaBeLife's products are derived from a family of patented molecules designed to block regulated necrosis, a type of regulated cell death. By targeting two synergistic pathways involved in various acute and chronic diseases, SeaBeLife aims to establish a new standard of care for patients with significant unmet medical needs. Through its research and development efforts, the company seeks to enhance patient outcomes and reduce complications associated with serious health conditions.

Dynacure is a clinical-stage drug development company dedicated to enhancing the lives of patients with rare and orphan diseases. The company focuses on creating innovative therapeutics, notably developing DYN101, an investigational antisense medicine aimed at modulating the expression of dynamin 2 for the treatment of Centronuclear Myopathies, in collaboration with Ionis Pharmaceuticals. In addition to DYN101, Dynacure is expanding its research portfolio to address other orphan disorders, including a program targeting hereditary spastic paraplegias caused by specific genetic mutations. Through its commitment to rare disease drug development, Dynacure seeks to provide effective treatment options for patients with limited therapeutic alternatives.

Deinove SA is a biotechnology company based in Grabels, France, focused on discovering, developing, and producing microbial-derived compounds for the health, nutrition, and cosmetics sectors. The company is advancing its portfolio of antibiotic candidates, including DNV3837, which is currently undergoing Phase II clinical trials for treating Clostridioides difficile infections. In the cosmetics arena, Deinove offers various bioactive ingredients such as PHYT-N-Resist, Luminity, HEBELYS, and BIOME Oléoactif, which serve functions ranging from anti-aging to balancing skin microbiota. Additionally, Deinove is exploring processes for producing natural ingredients for animal feed. The company has established partnerships with several organizations, including bioMérieux and the Institut Pasteur, to enhance its research and development initiatives. Founded in 2006, Deinove is committed to leveraging its bacterial biodiversity to create sustainable solutions across multiple industries.

Syndivia is a biotechnology company focused on developing innovative cancer therapeutics aimed at treating patients with challenging cancer indications. The company specializes in targeted antibody-drug conjugates (ADCs), designed to optimize drug-to-antibody ratios, thereby enhancing antitumor efficacy and safety. Syndivia's vision centers on leveraging the unique properties of tumor hallmarks and the tumor microenvironment to deliver effective treatments that improve outcomes for cancer patients.

Inotrem S.A. is a biotechnology company focused on developing innovative immunotherapies for acute and chronic inflammatory conditions. The company specializes in targeting the TREM-1 pathway to modulate unbalanced inflammatory responses. Inotrem's proprietary technology platform has led to the creation of nangibotide (LR12), a first-in-class TREM-1 inhibitor with potential applications in critical medical situations such as septic shock and myocardial infarction. Additionally, Inotrem is advancing research on new therapeutic modalities aimed at addressing chronic inflammatory diseases. By leveraging its expertise in immunomodulation, Inotrem aims to provide effective treatments for patients suffering from various inflammatory syndromes, enhancing critical care solutions in healthcare.

Fab’entech, founded in 2009 in Lyon, France, is a biopharmaceutical company that specializes in developing and commercializing innovative passive immunotherapeutic solutions. The company focuses on specific polyclonal immunoglobulins [F(ab’)₂], targeting emerging infectious diseases and certain drug intoxications. By utilizing highly purified fragments of horse-specific polyclonal immunoglobulins, Fab’entech aims to provide healthcare institutions with effective treatments for urgent medical situations. As a member of the LyonBiopôle cluster, the company is positioned within a vibrant network dedicated to advancing biopharmaceutical innovation.

Urania Therapeutics is a biopharmaceutical company focused on the identification and development of readthrough compounds aimed at treating genetic diseases and certain cancers. The company utilizes a proprietary structure-based drug design platform to create novel therapeutic treatments that address conditions caused by mutations, specifically those involving premature stop codons during protein synthesis. By enabling the production of full-length, functional proteins, Urania Therapeutics targets a range of monogenic disorders, including Duchenne muscular dystrophy and cystic fibrosis, as well as cancers linked to nonsense mutations. Through its innovative approach, the company seeks to restore normal protein production, offering potential new solutions for patients with these challenging genetic conditions.

Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G protein-coupled receptors (GPCRs), which are key drug targets in various diseases. Founded in 2001, the company specializes in developing small molecules for the treatment of central nervous system (CNS) disorders and cancer. It employs its proprietary technology platform, DTect-All, which enables the identification of orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs) that are challenging to discover using conventional methods. In addition, Domain Therapeutics offers BioSens-All, a platform to explore the signaling complexities associated with GPCR activation, enhancing its ability to address difficult targets, such as orphan and peptidic GPCRs.

VectivBio AG is a clinical-stage biotechnology company based in Basel, Switzerland, founded in 2019 as a spinout from Therachon. The company specializes in the discovery, development, and commercialization of innovative treatments for severe rare diseases, particularly those with significant unmet medical needs. Its lead product candidate, Apraglutide, is a synthetic GLP-2 analog designed to enhance the intestine’s ability to absorb fluids and nutrients, thereby reducing the reliance on parenteral support in patients with short bowel syndrome. VectivBio is dedicated to developing best-in-disease therapies that aim to meaningfully improve the lives of patients and their families, providing more than just incremental advancements over existing standard-of-care options.

ImCheck Therapeutics is a biopharmaceutical company based in Marseille, France, that specializes in developing immunotherapeutics aimed at addressing severe unmet medical needs, particularly in the field of immuno-oncology. Founded in 2015, the company focuses on designing and developing immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules. These innovative therapies engage γ9δ2 T cells, a specific type of immune cell, to effectively treat various cancers, including breast, gastric, and ovarian cancers, as well as other solid tumors. Through its advanced research and development efforts, ImCheck Therapeutics seeks to provide next-generation immunotherapeutics for patients suffering from immune-related diseases.

TISSIUM is a medical device company headquartered in Paris, France, focused on the development and commercialization of innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, provide strong adhesion to tissues, and enable rapid wound closure in the body's dynamic environments. TISSIUM leverages advanced research and intellectual property from renowned laboratories, including those of Robert Langer at MIT and Jeff Karp at Brigham and Women’s Hospital. Its technology platform includes a proprietary family of fully biosynthetic, biomorphic, and programmable polymers, which are tailored for tissue reconstruction across various clinical applications. Founded in 2013, TISSIUM is supported by leading healthcare investors and aims to address unmet clinical needs through its groundbreaking approach to wound management.

AlgoTherapeutix is a biotechnology company focused on developing innovative topical treatments for patients suffering from difficult-to-treat conditions, particularly complex pain syndromes. The company targets damaged nerve fibers in the skin to provide localized pain relief while minimizing the systemic side effects often associated with oral medications. AlgoTherapeutix is actively advancing its lead product, ATX01, which has received FDA approval to enter Phase 2 clinical trials for chemotherapy-induced peripheral neuropathy, a painful condition that lacks proven therapeutic options. Additionally, the company is exploring the potential of its treatments for erythromelalgia, a rare and debilitating disorder characterized by severe pain and inflammation. By tailoring therapies to the specific needs of patients, AlgoTherapeutix aims to improve treatment outcomes for individuals facing these challenging health issues.

Exeliom is a clinical-stage biopharmaceutical company based in Dijon, France, focused on developing innovative microbial therapies that utilize commensal bacteria as therapeutic agents. Founded in 2016, Exeliom aims to unlock the therapeutic potential of gut microbiota to enhance health and longevity. The company specializes in creating a new class of medicines known as Live Biotherapeutics, which are designed to deliver microbiome-based immunotherapy for conditions such as inflammatory bowel diseases and cancer, with an initial focus on Crohn's Disease. By harnessing the role of microbiota in the immune system, Exeliom strives to provide patients with advanced treatments that improve their quality of life.

ImCheck Therapeutics is a biopharmaceutical company based in Marseille, France, that specializes in developing immunotherapeutics aimed at addressing severe unmet medical needs, particularly in the field of immuno-oncology. Founded in 2015, the company focuses on designing and developing immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules. These innovative therapies engage γ9δ2 T cells, a specific type of immune cell, to effectively treat various cancers, including breast, gastric, and ovarian cancers, as well as other solid tumors. Through its advanced research and development efforts, ImCheck Therapeutics seeks to provide next-generation immunotherapeutics for patients suffering from immune-related diseases.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company is advancing several programs, including AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining stable calcium levels in the blood. Additionally, Amolyt Pharma is developing AZP-3404, a peptide with a novel mechanism of action designed to restore fat and glucose metabolism. Through its innovative approaches, the company aims to provide effective solutions for patients suffering from critical and rare metabolic conditions.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, specializing in the development of innovative therapies for advanced liver diseases and cancers associated with Claudin-1 (CLDN1) expression. Founded in 2019, Alentis focuses on addressing conditions such as liver fibrosis, cirrhosis, and liver cancer through the use of anti-CLDN1 antibody-drug conjugates and other targeted treatments. The company's unique approach combines clinically relevant read-outs with advanced techniques like single-cell RNA sequencing of patient liver tissues, aiming to reverse disease progression and improve patient outcomes. Alentis Therapeutics is recognized for its pioneering role in exploring anti-CLDN1 therapeutics, contributing to advancements in the treatment of fibrotic diseases and CLDN1-positive tumors.

NH TherAguix SAS is a clinical-stage pharmaceutical company based in Villeurbanne, France, focused on the development of nanomedicines for cancer treatment. The company specializes in creating innovative therapeutics that enhance radiotherapy for solid tumors. Its lead product, AGuIX, is a theranostic nanoparticle designed to improve the localization of tumors and optimize radiation therapy outcomes. By facilitating intravenous administration, AGuIX enables healthcare professionals to determine the best timing for irradiation, targets tumor tissues more effectively, and minimizes adverse effects on healthy tissues by reducing radiation doses. Founded in 2015, NH TherAguix is dedicated to advancing cancer treatment through its pioneering approach to combining imaging and radiotherapy.

Igyxos Biotherapeutics is a French company focused on developing pharmaceuticals and medical technologies to enhance human fertility. Established in 2017 and based in Nouzilly, Igyxos is dedicated to addressing the global demand for improved infertility solutions for both men and women. The company engages in all phases of drug development, from discovering promising biological targets to identifying lead compounds, including small molecules and monoclonal antibodies. These compounds are designed to interact with gonadotropins and hormones crucial for reproduction, thereby improving fertility treatments. Additionally, Igyxos supports the progression of potential drug candidates through pre-clinical and clinical development stages, while also acquiring intellectual property rights related to its innovative products and technologies.

Deinove SA is a biotechnology company based in Grabels, France, focused on discovering, developing, and producing microbial-derived compounds for the health, nutrition, and cosmetics sectors. The company is advancing its portfolio of antibiotic candidates, including DNV3837, which is currently undergoing Phase II clinical trials for treating Clostridioides difficile infections. In the cosmetics arena, Deinove offers various bioactive ingredients such as PHYT-N-Resist, Luminity, HEBELYS, and BIOME Oléoactif, which serve functions ranging from anti-aging to balancing skin microbiota. Additionally, Deinove is exploring processes for producing natural ingredients for animal feed. The company has established partnerships with several organizations, including bioMérieux and the Institut Pasteur, to enhance its research and development initiatives. Founded in 2006, Deinove is committed to leveraging its bacterial biodiversity to create sustainable solutions across multiple industries.

Alkion BioInnovations, established in March 2017, focuses on the development of innovative cannabinoid and pharmaceutical active pharmaceutical ingredients (APIs) through large-scale plant tissue production. The company employs proprietary semi-industrial technologies to produce natural plant active ingredients aimed at the pharmaceutical and agri-food markets. In addition to its work with cannabinoids, Alkion is also developing a novel plant-based high-intensity protein sweetener as a sugar replacement. The company has received numerous research and development grants and accolades, underscoring its commitment to advancing disruptive nutrition, non-cosmetic oils, and agrochemicals derived from plant sources.

Dynacure is a clinical-stage drug development company dedicated to enhancing the lives of patients with rare and orphan diseases. The company focuses on creating innovative therapeutics, notably developing DYN101, an investigational antisense medicine aimed at modulating the expression of dynamin 2 for the treatment of Centronuclear Myopathies, in collaboration with Ionis Pharmaceuticals. In addition to DYN101, Dynacure is expanding its research portfolio to address other orphan disorders, including a program targeting hereditary spastic paraplegias caused by specific genetic mutations. Through its commitment to rare disease drug development, Dynacure seeks to provide effective treatment options for patients with limited therapeutic alternatives.

ENYO Pharma SA is a clinical-stage biopharmaceutical company based in Lyon, France, founded in 2014 by scientists from the Infectiology Research Center. The company focuses on drug discovery and development for the treatment of acute and chronic viral infections, utilizing a unique platform to identify intracellular therapeutic targets and molecules. ENYO Pharma is developing a pipeline of drug candidates addressing various indications, including hepatitis B virus, nonalcoholic steatohepatitis, and oncology. Its lead compound, EYP001, is designed to modulate specific nuclear receptors, aiming to reduce viral reservoirs and inhibit harmful viral protein expression. The company is also advancing EYP002 through preclinical studies. ENYO Pharma collaborates closely with established research institutions and aims to conduct its molecules into Phase II clinical trials, striving to become a global leader in antiviral therapeutics.

TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in the development of cellular immunotherapies utilizing regulatory T cells (Tregs) to address severe chronic inflammatory diseases and autoimmune disorders. The company’s innovative approach includes the creation of Treg-based therapies with chimeric antigen receptors (CAR), targeting conditions such as graft rejection in solid organ transplantation, bullous pemphigoid, multiple sclerosis, and refractory Crohn's disease. TxCell has completed a Phase I/II study for its therapy in Crohn's disease and plans to advance further studies, including a Phase IIb trial in the same patient population and additional trials for rheumatoid arthritis. The company collaborates with various research institutions, enhancing its development capabilities. As of October 2018, TxCell operates as a subsidiary of Sangamo Therapeutics, Inc.

Step Pharma, incorporated in 2014 and based in Paris, France, focuses on developing innovative drugs for immunosuppressive therapies aimed at treating autoimmune diseases. As a spin-off of the Imagine Institute, the company emerged from research led by Pr. Alain Fischer on genetic immunodeficiencies. It operates as a joint venture with Sygnature Discovery, which provides integrated drug discovery resources, and Kurma Partners, a prominent investor in European healthcare and biotechnology. Step Pharma's proprietary small molecule therapeutics utilize a novel class of oral nucleotide synthesis inhibitors that target cytidine triphosphate synthase 1. This approach allows for the selective modulation of immune cell populations, such as T and B cells, enhancing treatment efficacy and therapeutic outcomes for patients with autoimmune conditions.

omicX is a company based in Le Petit Quevilly, France, that operates a bioinformatics platform designed to facilitate access to biotechnology tools. Established in 2012, omicX aims to harness the growing collective intelligence in bioinformatics to leverage biological Big Data for various applications across biotechnology, life sciences, medicine, agriculture, and industry. Its primary offering, OMICtools, serves as a valuable resource for scientists and developers, providing information on tools for storing, processing, and sharing significant volumes of biological data. The platform also enables users to engage with the scientific community by posting questions, sharing expertise, and providing feedback on available tools. This innovative approach has positioned omicX as a trusted leader and global reference in the bioinformatics field, attracting users from prestigious universities, medical institutions, pharmaceutical companies, and the biotech industry.

ImCheck Therapeutics is a biopharmaceutical company based in Marseille, France, that specializes in developing immunotherapeutics aimed at addressing severe unmet medical needs, particularly in the field of immuno-oncology. Founded in 2015, the company focuses on designing and developing immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules. These innovative therapies engage γ9δ2 T cells, a specific type of immune cell, to effectively treat various cancers, including breast, gastric, and ovarian cancers, as well as other solid tumors. Through its advanced research and development efforts, ImCheck Therapeutics seeks to provide next-generation immunotherapeutics for patients suffering from immune-related diseases.

OSE Immunotherapeutics SA is a clinical-stage biotechnology company based in Nantes, France, specializing in the development of innovative immunotherapies aimed at immune activation and regulation, particularly in the areas of immuno-oncology and autoimmune diseases. The company's product portfolio includes Tedopi, which is in Phase III clinical trials for lung cancer and Phase II for pancreatic cancer; BI 765063, currently in Phase I trials for solid tumors; and OSE-703, a humanized monoclonal antibody in preclinical development for various cancers. Additionally, OSE Immunotherapeutics is advancing FR104, which is in Phase I trials for rheumatoid arthritis, and OSE-127, a humanized monoclonal antibody in Phase I trials for inflammatory autoimmune diseases. The company collaborates with notable partners such as GERCOR, Memorial Sloan Kettering Cancer Center, Boehringer Ingelheim, Servier, and HalioDx. OSE Immunotherapeutics was previously known as OSE Pharma SA before its name change in May 2016.

Advicenne is a late-stage biopharmaceutical company established in 2007 and headquartered in Nîmes, France. It focuses on developing and commercializing innovative treatments for unmet medical needs in nephrology, particularly for orphan renal diseases and niche neurology indications. The company's lead drug candidate, ADV7103, is currently undergoing late-stage clinical trials for two specific conditions: distal renal tubular acidosis (dRTA) and cystinuria. Advicenne aims to create pediatric-friendly therapeutics that enhance the quality of life for patients from early childhood through adulthood.

TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in the development of cellular immunotherapies utilizing regulatory T cells (Tregs) to address severe chronic inflammatory diseases and autoimmune disorders. The company’s innovative approach includes the creation of Treg-based therapies with chimeric antigen receptors (CAR), targeting conditions such as graft rejection in solid organ transplantation, bullous pemphigoid, multiple sclerosis, and refractory Crohn's disease. TxCell has completed a Phase I/II study for its therapy in Crohn's disease and plans to advance further studies, including a Phase IIb trial in the same patient population and additional trials for rheumatoid arthritis. The company collaborates with various research institutions, enhancing its development capabilities. As of October 2018, TxCell operates as a subsidiary of Sangamo Therapeutics, Inc.

TISSIUM is a medical device company headquartered in Paris, France, focused on the development and commercialization of innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, provide strong adhesion to tissues, and enable rapid wound closure in the body's dynamic environments. TISSIUM leverages advanced research and intellectual property from renowned laboratories, including those of Robert Langer at MIT and Jeff Karp at Brigham and Women’s Hospital. Its technology platform includes a proprietary family of fully biosynthetic, biomorphic, and programmable polymers, which are tailored for tissue reconstruction across various clinical applications. Founded in 2013, TISSIUM is supported by leading healthcare investors and aims to address unmet clinical needs through its groundbreaking approach to wound management.

Alkion BioInnovations, established in March 2017, focuses on the development of innovative cannabinoid and pharmaceutical active pharmaceutical ingredients (APIs) through large-scale plant tissue production. The company employs proprietary semi-industrial technologies to produce natural plant active ingredients aimed at the pharmaceutical and agri-food markets. In addition to its work with cannabinoids, Alkion is also developing a novel plant-based high-intensity protein sweetener as a sugar replacement. The company has received numerous research and development grants and accolades, underscoring its commitment to advancing disruptive nutrition, non-cosmetic oils, and agrochemicals derived from plant sources.